Cargando…

Comprehensive Management of Acute Ischemic Stroke in Psoriatic Patient

BACKGROUND: Stroke is one of the top causes of death and disability in several nations. Patients with psoriasis are susceptible to multiple comorbidities, including stroke. In addition to acute ischemic stroke, psoriasis and chronic inflammation require comprehensive treatment. Here, we present a co...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasyid, Al, Mesiano, Taufik, Kurniawan, Mohammad, Hidayat, Rakhmad, Eddy Yunus, Reyhan, Novianto, Endi, Ocktafiani, Ocktafiani, Wiyarta, Elvan, Harris, Salim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017213/
https://www.ncbi.nlm.nih.gov/pubmed/36936469
http://dx.doi.org/10.1155/2023/6580971
_version_ 1784907529759752192
author Rasyid, Al
Mesiano, Taufik
Kurniawan, Mohammad
Hidayat, Rakhmad
Eddy Yunus, Reyhan
Novianto, Endi
Ocktafiani, Ocktafiani
Wiyarta, Elvan
Harris, Salim
author_facet Rasyid, Al
Mesiano, Taufik
Kurniawan, Mohammad
Hidayat, Rakhmad
Eddy Yunus, Reyhan
Novianto, Endi
Ocktafiani, Ocktafiani
Wiyarta, Elvan
Harris, Salim
author_sort Rasyid, Al
collection PubMed
description BACKGROUND: Stroke is one of the top causes of death and disability in several nations. Patients with psoriasis are susceptible to multiple comorbidities, including stroke. In addition to acute ischemic stroke, psoriasis and chronic inflammation require comprehensive treatment. Here, we present a comprehensive management case of a patient with an acute ischemic stroke and psoriasis. Case Presentation. A 42-year-old man came to the emergency department complaining of sudden left-sided weakness that started two and a half hours before being admitted to the hospital. The patient was treated with cyclosporine from 2013 to 2019 for a history of psoriasis. The patient was then treated for secondary stroke prevention using aspirin, vitamin B6, vitamin B12, folic acid, simvastatin, cyclosporine, and topical treatment. After two days of treatment, the patient's condition improved clinically, and he was discharged without further neurological deficits. As a home medication, the patient's cyclosporine was switched to the initial dose of methotrexate (7.5 mg/week) and titrated weekly to a response dose of 10 mg in the 10(th) week. After three months of follow-up, the patient's condition remained stable, devoid of similar symptoms or sequelae. CONCLUSIONS: Cyclosporine should only be used for a maximum of 1 year for stroke management with psoriasis and be substituted for other systemic agents such as methotrexate. In addition, anticoagulants, antihypertensive, antihyperlipidemic, vitamin B6, vitamin 12, and folic acid regimens are highly recommended for comprehensive therapy of cardiovascular comorbidities.
format Online
Article
Text
id pubmed-10017213
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-100172132023-03-16 Comprehensive Management of Acute Ischemic Stroke in Psoriatic Patient Rasyid, Al Mesiano, Taufik Kurniawan, Mohammad Hidayat, Rakhmad Eddy Yunus, Reyhan Novianto, Endi Ocktafiani, Ocktafiani Wiyarta, Elvan Harris, Salim Case Rep Dermatol Med Case Report BACKGROUND: Stroke is one of the top causes of death and disability in several nations. Patients with psoriasis are susceptible to multiple comorbidities, including stroke. In addition to acute ischemic stroke, psoriasis and chronic inflammation require comprehensive treatment. Here, we present a comprehensive management case of a patient with an acute ischemic stroke and psoriasis. Case Presentation. A 42-year-old man came to the emergency department complaining of sudden left-sided weakness that started two and a half hours before being admitted to the hospital. The patient was treated with cyclosporine from 2013 to 2019 for a history of psoriasis. The patient was then treated for secondary stroke prevention using aspirin, vitamin B6, vitamin B12, folic acid, simvastatin, cyclosporine, and topical treatment. After two days of treatment, the patient's condition improved clinically, and he was discharged without further neurological deficits. As a home medication, the patient's cyclosporine was switched to the initial dose of methotrexate (7.5 mg/week) and titrated weekly to a response dose of 10 mg in the 10(th) week. After three months of follow-up, the patient's condition remained stable, devoid of similar symptoms or sequelae. CONCLUSIONS: Cyclosporine should only be used for a maximum of 1 year for stroke management with psoriasis and be substituted for other systemic agents such as methotrexate. In addition, anticoagulants, antihypertensive, antihyperlipidemic, vitamin B6, vitamin 12, and folic acid regimens are highly recommended for comprehensive therapy of cardiovascular comorbidities. Hindawi 2023-03-08 /pmc/articles/PMC10017213/ /pubmed/36936469 http://dx.doi.org/10.1155/2023/6580971 Text en Copyright © 2023 Al Rasyid et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Rasyid, Al
Mesiano, Taufik
Kurniawan, Mohammad
Hidayat, Rakhmad
Eddy Yunus, Reyhan
Novianto, Endi
Ocktafiani, Ocktafiani
Wiyarta, Elvan
Harris, Salim
Comprehensive Management of Acute Ischemic Stroke in Psoriatic Patient
title Comprehensive Management of Acute Ischemic Stroke in Psoriatic Patient
title_full Comprehensive Management of Acute Ischemic Stroke in Psoriatic Patient
title_fullStr Comprehensive Management of Acute Ischemic Stroke in Psoriatic Patient
title_full_unstemmed Comprehensive Management of Acute Ischemic Stroke in Psoriatic Patient
title_short Comprehensive Management of Acute Ischemic Stroke in Psoriatic Patient
title_sort comprehensive management of acute ischemic stroke in psoriatic patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017213/
https://www.ncbi.nlm.nih.gov/pubmed/36936469
http://dx.doi.org/10.1155/2023/6580971
work_keys_str_mv AT rasyidal comprehensivemanagementofacuteischemicstrokeinpsoriaticpatient
AT mesianotaufik comprehensivemanagementofacuteischemicstrokeinpsoriaticpatient
AT kurniawanmohammad comprehensivemanagementofacuteischemicstrokeinpsoriaticpatient
AT hidayatrakhmad comprehensivemanagementofacuteischemicstrokeinpsoriaticpatient
AT eddyyunusreyhan comprehensivemanagementofacuteischemicstrokeinpsoriaticpatient
AT noviantoendi comprehensivemanagementofacuteischemicstrokeinpsoriaticpatient
AT ocktafianiocktafiani comprehensivemanagementofacuteischemicstrokeinpsoriaticpatient
AT wiyartaelvan comprehensivemanagementofacuteischemicstrokeinpsoriaticpatient
AT harrissalim comprehensivemanagementofacuteischemicstrokeinpsoriaticpatient